FOUR-YEAR OUTCOME OF 215 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FRONTLINE: A GIMEMA CML WORKING PARTY ANALYSIS